Podcasts about c max

Nouveaux pilotes, un brin déjantés, à bord de la Libre Antenne sur RMC ! Jean-Christophe Drouet et Julien Cazarre prennent le relais. Après les grands matchs, quand la lumière reste allumée pour les vrais passionnés, place à la Libre Antenne : un espace à part, entre passion, humour et dérision, débats enflammés, franc-parler et second degré. Un rendez-vous nocturne à la Cazarre, où l'on parle foot bien sûr, mais aussi mauvaise foi, vannes, imitations et grands moments de radio imprévisibles !

In this episode, host Alyssa Watson, DVM, welcomes Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP, to discuss her recent Clinician's Brief article, “Pharmacokinetics 101 for Veterinarians.” Dr. Davis' practical explanations will give you the right understanding about what happens to drugs once they're given to patients—and what you should do about it. This is like your conceptual intro class about all the stuff you skip over in drug monographs: Cmax, AUC, volume of distribution, etc. Resource: https://www.cliniciansbrief.com/article/veterinary-pharmacokinetics-guide Contact: podcast@instinct.vet Where To Find Us: Website: CliniciansBrief.com/Podcasts YouTube: Youtube.com/@clinicians_brief Facebook: Facebook.com/CliniciansBrief LinkedIn: LinkedIn.com/showcase/CliniciansBrief/ Instagram: @Clinicians.Brief X: @CliniciansBrief The Team: Alyssa Watson, DVM - Host Alexis Ussery - Producer & Multimedia Specialist

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Mandy Wiener speaks to Correctional Services Spokesperson, Singabakho Nxumalo about Thabo Bester being transferred to a C-Max, Ebongweni prison in Kokstad. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Therapeutic Plasma Exchange (TPE) has quickly become one of the most discussed longevity tools, bridging traditional medicine with cutting-edge regenerative therapies. In this episode, Dr. Greg Jones sits down with Dr. John Layke—Beverly Hills plastic surgeon and leading longevity physician—to unpack the science, clinical applications, and real-world results behind TPE. Dr. Layke explains how TPE works, why it has been used for decades in conventional medicine, and how modern research now points to its role in reducing inflammation, clearing immune complexes, and supporting metabolic health. You'll learn what is removed during plasma filtration, what patients commonly feel after a session, and how TPE interacts with other regenerative tools.The episode also explores how senescent cells, chronic inflammation, lifestyle choices, and hormone balance shape health span. Whether you're curious about emerging anti-aging therapies or evaluating whether TPE fits into your own health optimization plan, this discussion delivers a practical, science-driven guide to what's available now—and what the future of regenerative medicine may look like.

Parliament's ad hoc committee is likely to travel to the Kgosi Mampuru C-max Prison to hear testimony from remanded detainee, Vusimuzi "Cat" Matlala. The committee was established after KZN Police commissioner, Lt-General Nhlanhla Mkhwanazi's allegations of criminal infiltration, corruption and political interference in the justice system. Among others, Mkhwanazi alleged that the now placed on special leave Police Minister, Senzo Mchunu associated with individuals suspected to have links with drug cartels, such as Matlala. Matlala, who is facing charges of attempted murder, conspiracy to commit murder and money laundering, is being held in the Kgosi Mampuru C-Max prison. The committee met to discuss a draft report that will be presented to the Speaker of the National Assembly, Thoko Didiza, that informs a request for a second extension. The committee, investigating claims of criminal infiltration and corruption within South Africa's justice system, will visit the prison from the 26th to the 28th of November this month, to hear Matlala's testimony. Matlala, facing charges of attempted murder, conspiracy to commit murder and money laundering is expected to provide crucial evidence. For legal analysis on the matter Elvis Presslin spoke to Legal analyst, Melusi Xulu

Follow me: Facebook: fb.me/xabionly Twitter: twitter.com/xabionly Youtube: youtube.com/xabionly Mixcloud: mixcloud.com/xabionly Instagram: instagram.com/xabionly TRACKLIST: https://1001.tl/122v5s4t Spotify playlist: https://open.spotify.com/playlist/4STV7DPVgwI4ntvi1sQvjh?si=CU6lCNZcRkKiZytdXaI5TQ TRACKLIST: 01. Kirr Sounds - Looking For You [INTERPLAY FLOW] 02. Enlight - Bladerunner (Dark Mix) [AVA DEEP] 03. Laherte - BOUNCE [FUTURE RAVE] [PROMO OF THE WEEK] 04. R3HAB & Skytech & Pupa Nas T & Kevin McKay ft. Denise Belfon & Fideles - Work [GLASGOW UNDERGROUND] 05. Adam Sellouk & Zerky - Touch It [SPINNIN' DEEP] 06. Boris Way - Baby Baby [ULTRA] 07. Tujamo x RELOVA - Jump Into The Bag [HEXAGON] 08. James Hype - Don't Wake Me Up (NØSVN & Larza Remix) 09. Fedo vs. Swedish House Mafia & Connie Constance - I Will Survive (Heaven Takes You Home) (XABI ONLY Edit) 10. CMAX & HORU - In Your Eyes [EUPHONIX] 11. Westend, Darla Jade - Lighter [INSOMNIAC] 12. MORTEN, Luo Tianyi, CLSTR 56, Terry Zhong - High [LIQUID STATE] 13. Marquee - Slice History [INTERPLAY SOUL] 14. Stylo & Q.U.A.K.E - Loca [SIMULATE] 15. U-Jeen, Anton By - Labyrinth [INTERPLAY] 16. Anyma, Chris Avantgarde - Quantum [AFTERLIFE] 17. Josh Samuel - Mine Tonight [STEREOHYPE] 18. Bingo Players & JUSTNKAYSE - Memories [HYSTERIA] 19. Skytters & Glionna - Brand [SLAGELHAG] 20. Kriss Reeve - Bounce To The Beat [MUNICIPAL] 21. Glass Petals & Capozzi - More Life [CONFESSION] 22. Matt Guy & Volaris - Circles [1001REC.] 23. U:Phonics - Sky High (ALEX LNDN Remix) [LOW LIGHTS] 24. Kevin de Vries & Add-us - Nami [AFTERLIFE] 25. Stylo, Eli & Dani ft. Flauwher - Supersonic [SIMULATE] 26. KASIA, Charles D ft. Sarah De Warren - PSYCHO [DRUMCODE] [TRACK OF THE WEEK] 27. Lucas & Steve, DJ All Empty ft. Bella Perozzi - Bodies [SPINNIN'] 28. Baset - Drift [UPPERGROUND] [RELEASE OF THE WEEK] 29. Son of Son - HIDE [AFTERLIFE] 30. Fedo - Hear Me Now [FIND YOUR HARMONY] 31. UUFO & Shogun - Seven Days And One Week [REVEALED] 32. Karner H - Out of This World [HYPERSTARS] 33. MatricK - Sunshine [REVEALED] 34. KROMI - Simulation [REVEALED RADAR] 35. Stephen Hurtley - Don´t Let Me Go [DIM MAK] 36. Funk D, Botteghi - Anymore [REVEALED] 37. LUSSO - Bitches [SMASH THE HOUSE]

In this episode of the Health Accelerator Community (HAC) through Ageless Future, Regan Archibald explores the root causes of brain fog and cognitive decline, highlighting how chronic stress, poor sleep, and neuroinflammation can impair brain function. He explains the role of the hippocampus in memory and how changes in brain structure, particularly due to aging or conditions like Alzheimer's, can be detected early through symptoms such as forgetfulness, social withdrawal, and diminished focus. Regan discusses how environmental toxins, allergies, and lifestyle stressors disrupt neuroplasticity and outlines the EPIC framework—Emotions, Pain, Infections, Chemicals—as key inflammatory triggers. He introduces actionable strategies to restore brain health, including diagnostic testing, optimizing sleep, exercise, cortisol regulation, targeted nutrients, and innovative peptide and regenerative therapies like cerebrallysin, CMAX, and umbilical cord plasma. Listeners are encouraged to monitor their cognitive clarity over 30 days using wearables and journaling, with an invitation to explore deeper evaluation and support through upcoming retreats and personalized protocols. www.agelessfuture.com

In this episode I discuss R Shiny and how it can be used for building clinical pharmacology tools. I provide an overview of the technology, suggest a few example use cases, and then walk through a specific practical example of predicting AUC and Cmax for future doses from observed data. I end with a discussion of the benefits and challenges of using R Shiny for clinical pharmacology tools. Links discussed in the show:Basics about R ShinyShinyapps.io for hosting shiny apps Example R Shiny app by Samer Mouskassi: ggplot with your dataExample R Shiny app for AUC-Cmax predictions You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

- Interview with Diane Keyser on Healing and Natural Beauty (0:11) - Special Report on MSG Toxicity (0:54) - Engineer Recruitment and Project Delays (2:20) - Spiritual Reflections and Personal Anecdotes (5:36) - Joe Biden's Prostate Cancer Diagnosis and Second Amendment Victory (9:17) - Challenges in Health and Nutrition (10:04) - Exploring Different Belief Systems (20:07) - Experiments and Demonstrations (24:15) - The War on Cognition and MSG Toxicity (57:19) - Hidden Sources of MSG in Food (1:09:20) - Fast Food Chains and MSG (1:18:57) - Fast Food and MSG: A Comprehensive Overview (1:24:49) - Health Consequences of MSG (1:27:10) - Comparing Fast Food to Packaged Grocery Store Food (1:28:48) - The History and Impact of MSG (1:31:55) - Cultural and Historical Context of MSG (1:34:21) - Personal Experiences and Advocacy (1:37:57) - The Role of Peptides in Health and Wellness (2:10:21) - The Science Behind Peptides (2:12:25) - Practical Applications and Personal Testimonies (2:13:39) - The Future of Peptides and Health Advocacy (2:13:53) - Body as a Molecular Factory (2:14:47) - Peptides and Their Miraculous Effects (2:43:11) - C Max and Its Cognitive Benefits (2:44:50) - Oxytocin and Its Role in Hormone Regulation (2:48:01) - Peptides vs. Pharmaceuticals (2:49:23) - BPC 157 and Its Benefits for Injuries (2:51:10) - Environmental Toxins and Their Impact on Health (2:56:18) - Personalized Peptide Therapy (3:05:05) - Injectable Peptides and Their Administration (3:08:05) - Conclusion and Call to Action (3:20:51) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

In this episode of the Unreasonable Health Podcast, Regan Archibald dives into cutting-edge strategies for cognitive enhancement, focusing on neuroinflammation, gut health, and brain optimization. He explores the role of Peptides like C-Max, Cerebrolysin, and LL-37, as well as innovative treatments such as umbilical cord plasma and intranasal NAD. Regan also discusses the impact of mold exposure, heavy metals, and gut dysbiosis on brain function while sharing actionable tips for improving memory, focus, and mental clarity. Tune in to discover powerful tools to upgrade your brain health and performance!

Los monovolúmenes fueron una verdadera revolución como coches familiares. El primer monovolumen de gran éxito en los EE.UU. de Norteamérica fue la Chrysler Voyager, pero el que se considera el primer monovolumen de la historia es la Renault Espace… y ahora prácticamente han desaparecido… ¿el motivo? No me gusta señalar, pero… los han asesinado los SUV. La idea de un monovolumen, que es crecer a lo alto, llevar a los pasajeros más “sentados” en un “silla”, con comillas, cómoda, que no “repanchingados” en un butacón… Algo tan sencillo permitía en la misma longitud conseguir más espacio para los pasajeros, bien para ganar confort, bien para poner una tercera fila de asientos y-o bien para tener un maletero cavernoso. Pero no solo eso, contar con una plataforma plana y con un poco de imaginación era posible que en un mismo coche contase con diferentes configuraciones, desde 4 amplísimas plazas a 7 u 8, o tener 5 con un supermaletero o 2 y una capacidad propia de una furgoneta… en este la Espace fue, quizás, la más innovadora. Si entráis en la “Wikipedia” y buscáis “Renault Espace, veréis que pone en el periodo de producción: 1984-Presente”. Pues no es cierto del todo. Si que hay en la actualidad un modelo de Renault con ese nombre, pero desde 2023 ya no es un monovolumen… entraremos más en detalle más adelante. También hemos contado que la idea original surge de MATRA, una empresa a la hemos dedicado un vídeo y que decide además de hacer misiles y coches deportivos, diseñar algo innovador. Tan innovador que a Peugeot le echa para atrás, pero no a los más valientes dirigentes de Renault. La Espace era muy innovadora, con una carrocería de fibra sobre un chasis de acero, con un diseño muy cuadrada pero no exento de atractivo y sobre todo con un modularidad interior hasta entonces nunca vista. Era posible, por ejemplo, poner tres asientos uno tras otros en el lado del conductor y dejar el lateral derecho libre para meter, por ejemplo, una tabla de surf… Mover los asientos era fácil y rápido, podía hacer una mini oficina y además el interior era muy cuidado y muy luminoso. Los comienzos del Espace no fueron fáciles, tardó en “entrar” en el mercado, incluso por parte de los fabricantes, digo “los” porque la mecánica era Renault, pero se montaban en MATRA, hubo momentos de duda… pero ya entrados en el segundo año comenzaron a crecer las ventas. El éxito tardó, pero fue enorme. Por un lado, para muchos era un vehículo “diferente”, en algunos mercados casi “Premium” y para otros era el concepto de vehículo más práctico, sobre todo si tenías familia, por su gran espacio, confort y modularidad. ¿Y qué pasa cuando un concepto innovador triunfa? Pues que rápidamente le salen imitadores y la idea se traspasa a otros segmentos. Asistimos a un verdadero “boom” de los monovolúmenes y se puede decir que entre los años 80 y los 2000, todas las marcas tuvieron sus modelos monovolumen. Renault lanzó en 1996 el Scénic, una especie de mini-Espace que rápidamente tuvo un gran éxito… Al Scénic rápidamente le salieron competidores como los Peugeot 5008, Toyota Corolla y VW Touran. Ford lo hizo bien, porque lanzó dos buenos monovolúmenes, en el segmente medio el C-Max y por encima el Galaxy, con motorizaciones que llegaban a la versión V6 de 2.8 litros y más de 200 CV. Ford lanzó en 2006 un monovolumen con aires premium y deportivos, que fue el S-Max, con un buen bastidor y excelentes motores, desde un diésel 1.8 de 125 CV al magnifico 5 en línea de gasolina, 2.5 litros y 220 CV… un coche realmente interesante. Y no me olvido del Seat Altea. Se puede decir que los monovolúmenes fueron los reyes y vivieron su auge la dos última décadas del Siglo XX y a partir de ahí se inició su caída… hasta llegar a nuestros días, donde hay una oferta mínima y no se ven monovolúmenes nuevos, si usados, por las calles. Porque técnicamente un monovolumen es un coche que aprovecha más el espacio a lo alto para ganarlo a lo largo, mientras que un SUV, insisto, técnicamente no es más que un break más alto. La conclusión es que los SUV son modelos “aspiracionales”, no son modelos como los monovolúmenes cuyo mayor argumento de compra era su practicidad, sino que un SUV se supone que “mola”, es grandote, con aire de TT, imponente y parece que, si no tienes un SUV, no eres nadie. Desde el punto de vista técnico y práctico un monovolumen es más interesante que un SUV, pero, para bien más que para mal, los automóviles tienen encanto más allá de la lógica. Coche del día. Honda sigue ofreciendo un monovolumen que, por concepto, me recuerda a mi ex Ford Galaxy V6, pero más moderno y refinado: El Honda Odyssey con motor V6 de 3,6 y 280 CV y con caja de cambios automática de 10 velocidades.

Los monovolúmenes fueron una verdadera revolución como coches familiares. El primer monovolumen de gran éxito en los EE.UU. de Norteamérica fue la Chrysler Voyager, pero el que se considera el primer monovolumen de la historia es la Renault Espace… y ahora prácticamente han desaparecido… ¿el motivo? No me gusta señalar, pero… los han asesinado los SUV. La idea de un monovolumen, que es crecer a lo alto, llevar a los pasajeros más “sentados” en un “silla”, con comillas, cómoda, que no “repanchingados” en un butacón… Algo tan sencillo permitía en la misma longitud conseguir más espacio para los pasajeros, bien para ganar confort, bien para poner una tercera fila de asientos y-o bien para tener un maletero cavernoso. Pero no solo eso, contar con una plataforma plana y con un poco de imaginación era posible que en un mismo coche contase con diferentes configuraciones, desde 4 amplísimas plazas a 7 u 8, o tener 5 con un supermaletero o 2 y una capacidad propia de una furgoneta… en este la Espace fue, quizás, la más innovadora. Si entráis en la “Wikipedia” y buscáis “Renault Espace, veréis que pone en el periodo de producción: 1984-Presente”. Pues no es cierto del todo. Si que hay en la actualidad un modelo de Renault con ese nombre, pero desde 2023 ya no es un monovolumen… entraremos más en detalle más adelante. También hemos contado que la idea original surge de MATRA, una empresa a la hemos dedicado un vídeo y que decide además de hacer misiles y coches deportivos, diseñar algo innovador. Tan innovador que a Peugeot le echa para atrás, pero no a los más valientes dirigentes de Renault. La Espace era muy innovadora, con una carrocería de fibra sobre un chasis de acero, con un diseño muy cuadrada pero no exento de atractivo y sobre todo con un modularidad interior hasta entonces nunca vista. Era posible, por ejemplo, poner tres asientos uno tras otros en el lado del conductor y dejar el lateral derecho libre para meter, por ejemplo, una tabla de surf… Mover los asientos era fácil y rápido, podía hacer una mini oficina y además el interior era muy cuidado y muy luminoso. Los comienzos del Espace no fueron fáciles, tardó en “entrar” en el mercado, incluso por parte de los fabricantes, digo “los” porque la mecánica era Renault, pero se montaban en MATRA, hubo momentos de duda… pero ya entrados en el segundo año comenzaron a crecer las ventas. El éxito tardó, pero fue enorme. Por un lado, para muchos era un vehículo “diferente”, en algunos mercados casi “Premium” y para otros era el concepto de vehículo más práctico, sobre todo si tenías familia, por su gran espacio, confort y modularidad. ¿Y qué pasa cuando un concepto innovador triunfa? Pues que rápidamente le salen imitadores y la idea se traspasa a otros segmentos. Asistimos a un verdadero “boom” de los monovolúmenes y se puede decir que entre los años 80 y los 2000, todas las marcas tuvieron sus modelos monovolumen. Renault lanzó en 1996 el Scénic, una especie de mini-Espace que rápidamente tuvo un gran éxito… Al Scénic rápidamente le salieron competidores como los Peugeot 5008, Toyota Corolla y VW Touran. Ford lo hizo bien, porque lanzó dos buenos monovolúmenes, en el segmente medio el C-Max y por encima el Galaxy, con motorizaciones que llegaban a la versión V6 de 2.8 litros y más de 200 CV. Ford lanzó en 2006 un monovolumen con aires premium y deportivos, que fue el S-Max, con un buen bastidor y excelentes motores, desde un diésel 1.8 de 125 CV al magnifico 5 en línea de gasolina, 2.5 litros y 220 CV… un coche realmente interesante. Y no me olvido del Seat Altea. Se puede decir que los monovolúmenes fueron los reyes y vivieron su auge la dos última décadas del Siglo XX y a partir de ahí se inició su caída… hasta llegar a nuestros días, donde hay una oferta mínima y no se ven monovolúmenes nuevos, si usados, por las calles. Porque técnicamente un monovolumen es un coche que aprovecha más el espacio a lo alto para ganarlo a lo largo, mientras que un SUV, insisto, técnicamente no es más que un break más alto. La conclusión es que los SUV son modelos “aspiracionales”, no son modelos como los monovolúmenes cuyo mayor argumento de compra era su practicidad, sino que un SUV se supone que “mola”, es grandote, con aire de TT, imponente y parece que, si no tienes un SUV, no eres nadie. Desde el punto de vista técnico y práctico un monovolumen es más interesante que un SUV, pero, para bien más que para mal, los automóviles tienen encanto más allá de la lógica. Coche del día. Honda sigue ofreciendo un monovolumen que, por concepto, me recuerda a mi ex Ford Galaxy V6, pero más moderno y refinado: El Honda Odyssey con motor V6 de 3,6 y 280 CV y con caja de cambios automática de 10 velocidades.

In this episode, Regan Archibald dives deep into the world of brain-boosting peptides, nootropics, and biohacking strategies for cognitive enhancement. He explores the importance of cycling nootropics like Cmax, Selank, and NAD+ to prevent diminishing returns and optimize brain function. Regan highlights the role of intranasal glutathione and NAD+ in reducing oxidative stress, improving neuroprotection, and enhancing mitochondrial function. He also introduces cutting-edge peptides like FGL, which show promise in neuroregeneration and cognitive repair. To provide measurable insights into brain health, he discusses the upcoming integration of NeuroCatch technology at East West, allowing for real-time tracking of cognitive improvements. Listeners are challenged to incorporate brain-healthy foods like eggs, blueberries, and dark chocolate while experimenting with nootropics to enhance focus, memory, and overall mental clarity.

A selection of my favourite tracks this month. Along with guest producer Sheps on deck to spin some tunes half way through. Recorded live at bside radio in Vancouver. Cmax music aka City Props https://on.soundcloud.com/yX6nNTo8FcFBvkaB6 Instagram https://www.instagram.com/maxedoutcrew/profilecard/?igsh=MWZycWtwbmc4a2drdg== Sheps https://on.soundcloud.com/gJ99fqK8uoQBcxtCA Sheppard records https://on.soundcloud.com/7QWMyfhatfWvVq357 Instagram https://www.instagram.com/jamiesheps?igsh=MTJxbXNmZXIyaWtmag== ⚡️Like the Show? Click the [Repost] ↻ button so more people can hear it!

In today's episode, host Chris Duffin dives deep into the fascinating world of cognitive enhancement with special guest Anthony Castor. We'll explore a range of nootropic peptides and supplements designed to boost brain function, resilience, and overall well-being. Chris and Anthony discuss such potent peptides as C Max and Celnac, revealing their roles in cognitive enhancement, neuroprotection, and stress resistance. We'll learn about Synapsin's ginsenoside RG3, and its anti-aging properties, and the intriguing nootropic properties of NewPEPT. Listen as Anthony shares personal anecdotes about using compounds like Dihexa for synapse formation and modafinil for enhancing wakefulness and cognitive performance. Throughout the conversation, we'll also delve into the science behind these compounds, examining their neurotransmitter modulation, neuroprotection, and practical applications for high-stress jobs, shift work, and productivity boosts. Additionally, we'll cover lifestyle practices that complement these cognitive enhancers, emphasizing the importance of sleep, hydration, and a balanced diet.   This episode of the ARCHITECT of RESILIENCE podcast is available on Apple, Spotify & YouTube, and is sponsored by  @marekhealth : Performance. Longevity. Optimization.

On March 18, 2024, Caremax revealed its earnings report, during which CEO Carlos de Solo emphasised the critical importance of robust relationships within their operational network. He stated, "More generally, these developments have reaffirmed to us the importance of strong relationships in our business. With our legacy health plans, we have a good history of alignment and a common view toward the long-term benefits of our high-touch model. With our new payer partners, we couldn't be more excited to embark on that same journey. With any partner, our efforts are most successful when our payers equip us with the right data, tools, and access; and share in the upfront investments needed to manage risk." Following this, CareMax demonstrated its organizational resilience and agility, consistently confronting fiscal challenges, refining operations, and laying groundwork for future stability and prosperity. This is despite a financially challenging period for the organization. CareMax is focusing on operational efficiency and profitability as part of its strategic intent. This has led to an intensive examination of their cost structure, enhancing operations across current business divisions, and examining strategic options to maximize asset value. It's initiatives such as refining its workforce, implementing cost-cutting measures, and attaining a five-star quality rating for their care centers underline CareMax's adherence to quality service delivery and fiscal sustainability. Though consumer behaviors did not form a bulk of CareMax's address, there were revealing insights into anticipated strategic shifts, and focus areas. The organization expressed an intention to focus on structural modifications in business operations, monetize key assets, and recalibrate the company's capital structure. Conversations around strategizing asset value maximization are currently underway. Though these are early days, successful negotiations could unearth new opportunities and boost shareholder interests. The strategizing at CareMax seems to indicate a sturdy and adaptable approach towards industry fluctuations and value creation. To conclude, CareMax's report suggests that 2024 is a transition year for the company as it grapples with industry trends. Its ongoing initiatives and plans for structural changes show an intention to adapt, but the path towards long-term goals will be dependent on both internal strategies and external market factors. While CareMax positions itself optimistically, the journey is likely to be one of persistent adaptation and continuous improvement. CMAX Company info: https://finance.yahoo.com/quote/CMAX/profile For more PSFK research : www.psfk.com  This email has been published and shared for the purpose of business research and is not intended as investment advice.

On this episode of Wrench Jockey Radio, Goose and Dakota finally get to continue interviewing a guest that has been on before. Built Cmax is back, and he's got more stuff to talk about! Covering not only his mechanic endeavors and social media, but a recent happening that will keep you all very intrigued. Stay tuned to Wrench Jockey Radio for even more!

Serial Killer Moses Sithole Documentary The "Ted Bundy Of South Africa" Born in South Africa on November 17, 1964, Moses Sithole is considered one of South Africa's worst serial killers. In 1997, Sithole was found guilty of 38 murders and 40 rapes. A significant number of Sithole's victims were never identified. Sithole would gain access to victims by pretending to be a businessman and offering them work, going so far as to invent a fictional charity organization. Once he had gained their trust, he would offer to walk them through a veld (an Afrikaans word literally meaning "field") to the "business headquarters" until they were out of sight and hearing range; he would then overpower, rape and strangle them. By 1995, he had claimed over 30 victims, igniting a nationwide panic. In some cases, he would call the victim's family and taunt them. In August 1995, Sithole was identified as having been seen with one of the victims; police soon discovered details of his fake business and previous rape conviction. Panicked, he went on the run. He called journalist Tamsen de Beer and identified himself as the killer. At the third call, he gave De Beer a number to call back. The police rushed to the pay phone he was calling from, but they were too late. Shortly after that Sithole contacted his brother-in-law, who promised him to help him get a gun and arranged a meeting. The brother-in-law notified the police, but Sithole sensed a trap at the meeting spot and ran.  Police shot him twice when he charged them with an axe, wounding him before taking him into custody. He eventually confessed to the murders. On December 5, 1997, Sithole was sentenced to 50 years imprisonment for each of the 38 murders, 12 years imprisonment for each of the 40 rapes, and five years imprisonment for each of the six robberies. Since his sentences run consecutively, the total effective sentence is thus one of 2,410 years. Justice David Carstairs ordered that Sithole would be required to serve at least 930 years before being eligible for parole (in around 2927). He is incarcerated in C-Max, the maximum security section of Pretoria Central Prison, during this time, press reports stated that he was HIV positive. He receives treatment for the virus while in prison, but his wife and child died of the disease because law abiding citizens do not automatically qualify for any sort of health care coverage until age 65. Serial Killer Moses Sithole Documentary The Ted Bundy Of South Africa

Kanna | Can This South African Succulent Make You a Better Dancer? Kanna is a unique succulent plant, originating from South Africa. It has been used as a mood and energy boosting botanical for thousands of years by the KhoiSan people of South Africa, for dancing ceremonies and as a hunting aid. In this month's podcast episode, Emiel (Nootropics Depot Product Specialist) and Erika discuss the history of Kanna, its pharmacokinetics and mechanisms of action, and how Kanna provides a distinctly uplifting effect from its serotonergic activity. Tune in to learn about dosing Kanna, taking Kanna at night clubs in Amsterdam, mesembrine, mesembrenone, and Delta 7 mesembrenone, and why you should try Kanna for its pro-social benefits. Follow In Search of Insight on Instagram https://www.instagram.com/insearchofinsight?igsh=ZGNjOWZkYTE3MQ%3D%3D&utm_source=qr Buy Full Spectrum Kanna Tablets from Nootropics Depot https://nootropicsdepot.com/full-spectrum-kanna-extract-quick-dissolve-tablets/ Read Nootropics Depot's Blog on Kanna https://nootropicsdepot.com/kanna-lift-mood-and-lower-stress Podcast Chapters 00:00 Introduction 04:10 Dosing Kanna 09:40 Stimulating Effects of Kanna 11:50 Fat or Water Soluble? Bioavailbility of Kanna 17:30 Oral & Sublingual Administration 18:53 Pharmacokinetics - T Max and C Max 34:00 Caffeine Usage and Concentration 36:00 Dynamax Pharmicokinetics 38:45 Mood, Focus, Energizing, Pro-Social Effects of Kanna 43:00 Traditional Uses of Kanna, Amanita Muscaria, Kava50:00 Neuroscience of Kanna - Neurotransmitter Releaser 53:07 Mesembrine acts as a VMAT2 Upregulator 1:03:40 Testing Mesembrine Content of Kanna Extracts 1:14:10 Cultivars of Kanna - Sceletium tortuosum 1:14:54 What Sets Nootropics Depot's Kanna Extract Apart 1:18:22 Beta Testing and Initial Bio-assaying 1:25:31 Kanna as a Subtle Appetite Suppresant 1:33:11 Emiel & Erika's Current Occasional Supplements 1:47:07 Emiel & Erika's Daily Supplement Stack 1:57:24 Conclusion

On this episode of Wrench Jockey Radio, Goose and Dakota bring on a new friend that they have been talking about swindling onto the show for a little while! His real name remains anonymous, but The Built CMax came onto the podcast to halfways school the boys on their automotive knowledge and best them in the “shit box count.” We aren't done talking to our newfound pal just yet. So you'll have to tune again to hear even more from The Built CMax, only here on Wrench Jockey Radio!

Brock & Salk are blown away by how unbelievable this Mariners starting pitching rotation has been and compares them to some of the best teams in the 90s before being joined by former Seahawks C Max Unger (who makes his home in Hawaii) to discuss the recent fires and fundraising support. See omnystudio.com/listener for privacy information.

Brock & Salk are blown away by how unbelievable this Mariners starting pitching rotation has been and compares them to some of the best teams in the 90s before being joined by former Seahawks C Max Unger (who makes his home in Hawaii) to discuss the recent fires and fundraising support. See omnystudio.com/listener for privacy information.

In this episode, I discuss some nuances of non-compartmental analysis or NCA. I am going to focus on three separate parameters: Cmax, AUC, and the terminal elimination rate constant. These three are the most commonly used parameters to describe drug exposure. I'll discuss the basic methodology for each and then discuss challenges that may arise when you are performing an analysis. Links discussed in the show: Images mentioned in the podcast Derivation of logarithmic AUC Calculating the elimination rate constant You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved

Do you know that supplementing NAD or glutathione with frequent IVs might be hurting your cell's ability to adapt? Join Dr. Jeffrey Gladden, Steve Reiter and Dr. Seeds in this episode of the Gladden Longevity Podcast. Dr. Seeds is a board-certified orthopedic surgeon practicing medicine for over 27 years and the Founder and Medical Director of the Seeds Scientific Research & Performance Mastermind. He has been honored at the NFL Hall of Fame for his medical expertise and in treating professional athletes. He serves as Professional Medical Consultant for the NHL, MLB, NBA, and NBC's Dancing with The Stars. Dr. Seeds is also a medical researcher and continues to write and publish in the NIH and other medical journals. He is also the author of Peptide Protocols Vol.1, the world's first handbook about peptides written for practitioners. Today at the Seeds Scientific Research and Performance Institute, he is dedicated to bringing Cellular Medicine and the study of Epigenome to the forefront of the medical community through research, training, and improved patient outcomes. His practice is at the Olympic training facility: Spire Institute Geneva, OH, and at the Redox Medical Group, Beverly Hills, CA. This episode discusses how cellular redox is quickly going to become the health goal and how this is where disease, aging, and cancer starts, and that it is also where we can find solutions. As the podcast progresses, they talk about our cell's main job, the balance and the imbalance of oxidation and reduction, and the benefits of achieving cellular redox. They explore various peptides and their ability to maintain homeostasis of redox, improve gut health, decrease anxiety, and aid in recovery after injury or training. Moreover, they touch on the importance of addressing gut health to tackle immune issues and offer dosage recommendations for peptides.   Listen to this episode to learn about making 100 the new 30 and living young for a lifetime!    Dr. Gladden mentions that Seeds was the one that certified him in peptides. (1:15)  Dr. Gladden explains that we make peptides in our bodies. (2:24)  Dr. Gladden welcomes Dr. Seeds. (4:10)  Dr. Gladden explains cellular redox. (6:14)  Dr. Seeds shares that his mission was to introduce people to cellular medicines. (8:09)  Dr. Seeds speaks about making microfilaments in a cell to keep the structure of the cell symmetrical. (10:35)  Dr. Seeds shares that if you're regulating the infrastructure of a cell to keep it at its optimal, and you're keeping the signaling at its optimal, then you're reducing cellular redox issues, and you're reducing problems that create, like fibrosis. (12:40)  Dr. Gladden asks Dr. Seed about the interplay between GHKCU and BPC 157. (15:40)  Dr. Gladden discloses his observations that injuries seem to heal faster with the use of peptides. (18:03)  Dr. Gladden shares that he wakes up feeling 27 every day. (19:50)  Dr. Gladden goes over what being nominated means. (21:25)  Dr. Gladden emphasizes that people could make a case for using BPC on a daily basis. (24:13)  Dr. Seeds says T-regs cells are masters of immune tolerance. (28:00)  Dr. Seeds reveals the discovery of zonulin, which is a toxin from the cellular connection in the bowel. (32:25)  Dr. Seeds advises that people need to focus on the gut with lots of immune issues. (35:15)  Dr. Seeds discloses a peptide that helps with leaky gut. (37:36)  Dr. Seeds speaks about one of the best peptides available that can be used intranasal or subcutaneously. (41:28)  Dr. Seeds reveals that BDNF is a big player in anxiety and depression. (44:10)  Dr. Seeds advises that you must be careful with CMAX because it's more of an activator. (47:40)  Dr. Seeds refers to how working with younger kids is a game changer. (50:25)  Dr. Seeds says there are good and bad aspects of nicotinamide. (54:25)  Dr. Seeds spells out one of the best peptides we have if you know how to use it. (57:00)  Dr. Seeds refers to an incredible peptide that only needs to be used for short periods. (59:00)  Steve announces that Dr. Seeds has a book on peptides and thanks everyone for listening. (1:00:07)           Visit our website, www.gladdenlongevitypodcast.com, for more information on this episode and other episodes as well. Click on the link to let us know what you'd like us to talk about on the podcast too!                      Follow us on social media!                                Instagram: @gladdenlongevity                                Twitter: @gladdenlongevit                                Facebook: @GladdenLongevity                         LinkedIn: @GladdenLongevity    For more information on our practice or how to become a client, visit:   www.gladdenlongevity.com  Call us: 972-310-8916  Or email us: info@gladdenlongevity.com    To learn more about Dr. Seeds and his work, check out the following:    https://seeds.md/  For health practitioners: ssrpinstitute.org  For health enthusiasts: redoxmedicalgroup.com  IG: @williamaseedsmd @ssrpinstitute @redoxmedicalgroup    DISCOUNT:   Podcast10 (10% off your purchase at the Gladden Longevity Supplement shop (https://gladdenlongevityshop.com/) 

Serial Killer Moses Sithole Documentary The "Ted Bundy Of South Africa"Born in South Africa on November 17, 1964, Moses Sithole is considered one of South Africa's worst serial killers. In 1997, Sithole was found guilty of 38 murders and 40 rapes. A significant number of Sithole's victims were never identified. Sithole would gain access to victims by pretending to be a businessman and offering them work, going so far as to invent a fictional charity organization. Once he had gained their trust, he would offer to walk them through a veld (an Afrikaans word literally meaning "field") to the "business headquarters" until they were out of sight and hearing range; he would then overpower, rape and strangle them. By 1995, he had claimed over 30 victims, igniting a nationwide panic. In some cases, he would call the victim's family and taunt them. In August 1995, Sithole was identified as having been seen with one of the victims; police soon discovered details of his fake business and previous rape conviction. Panicked, he went on the run. He called journalist Tamsen de Beer and identified himself as the killer. At the third call, he gave De Beer a number to call back. The police rushed to the pay phone he was calling from, but they were too late. Shortly after that Sithole contacted his brother-in-law, who promised him to help him get a gun and arranged a meeting. The brother-in-law notified the police, but Sithole sensed a trap at the meeting spot and ran. Police shot him twice when he charged them with an axe, wounding him before taking him into custody. He eventually confessed to the murders. On December 5, 1997, Sithole was sentenced to 50 years imprisonment for each of the 38 murders, 12 years imprisonment for each of the 40 rapes, and five years imprisonment for each of the six robberies. Since his sentences run consecutively, the total effective sentence is thus one of 2,410 years. Justice David Carstairs ordered that Sithole would be required to serve at least 930 years before being eligible for parole (in around 2927). He is incarcerated in C-Max, the maximum security section of Pretoria Central Prison, during this time, press reports stated that he was HIV positive. He receives treatment for the virus while in prison, but his wife and child died of the disease because law abiding citizens do not automatically qualify for any sort of health care coverage until age 65.true crime stories,serial killer documentary,serial killer documentary 2023,true crime stories podcast 2023,serial killers,serial killer moses sithole documentary,the ted bundy of south africa,true crime documentary 2023,serial killers documentaries,moses sithole documentary,moses sithole today,moses sithole south africa,moses sithole now,south africa serial killer,moses sithole,moses sithole victims,moses sithole story,true crime stories youtubers

Serial Killer Moses Sithole Documentary The "Ted Bundy Of South Africa"Born in South Africa on November 17, 1964, Moses Sithole is considered one of South Africa's worst serial killers. In 1997, Sithole was found guilty of 38 murders and 40 rapes. A significant number of Sithole's victims were never identified. Sithole would gain access to victims by pretending to be a businessman and offering them work, going so far as to invent a fictional charity organization. Once he had gained their trust, he would offer to walk them through a veld (an Afrikaans word literally meaning "field") to the "business headquarters" until they were out of sight and hearing range; he would then overpower, rape and strangle them. By 1995, he had claimed over 30 victims, igniting a nationwide panic. In some cases, he would call the victim's family and taunt them. In August 1995, Sithole was identified as having been seen with one of the victims; police soon discovered details of his fake business and previous rape conviction. Panicked, he went on the run. He called journalist Tamsen de Beer and identified himself as the killer. At the third call, he gave De Beer a number to call back. The police rushed to the pay phone he was calling from, but they were too late. Shortly after that Sithole contacted his brother-in-law, who promised him to help him get a gun and arranged a meeting. The brother-in-law notified the police, but Sithole sensed a trap at the meeting spot and ran. Police shot him twice when he charged them with an axe, wounding him before taking him into custody. He eventually confessed to the murders. On December 5, 1997, Sithole was sentenced to 50 years imprisonment for each of the 38 murders, 12 years imprisonment for each of the 40 rapes, and five years imprisonment for each of the six robberies. Since his sentences run consecutively, the total effective sentence is thus one of 2,410 years. Justice David Carstairs ordered that Sithole would be required to serve at least 930 years before being eligible for parole (in around 2927). He is incarcerated in C-Max, the maximum security section of Pretoria Central Prison, during this time, press reports stated that he was HIV positive. He receives treatment for the virus while in prison, but his wife and child died of the disease because law abiding citizens do not automatically qualify for any sort of health care coverage until age 65.true crime stories,serial killer documentary,serial killer documentary 2023,true crime stories podcast 2023,serial killers,serial killer moses sithole documentary,the ted bundy of south africa,true crime documentary 2023,serial killers documentaries,moses sithole documentary,moses sithole today,moses sithole south africa,moses sithole now,south africa serial killer,moses sithole,moses sithole victims,moses sithole story,true crime stories youtubers

Grateful to be back and talking at those who are willing to listen. Today's episode is a whirlwhind of emotions with a sick Spooky to CMax's topic and news anxiety to full-blown discussions on The Last of Us (2023), episodes 2 and 3, and Infinity Pool. As always, check out all the socials (link below), leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! INTRO: 00:00:24 NEWS: 00:06:25 TLOU: 00:29:15 INFINITY POOL: 01:10:14 https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://podcasters.spotify.com/pod/show/matrimony-madness/message

Sunday was an entertainment emotional storm that was weathered and the gang are happy to have provided an episode for everyone this week. This one is a little off the rails dealing in ASMR and entertainment abuse hot takes. Spooky and CMax dive into FIVE sinister sneaks this episode as well as a discussion into the juggernaut that is the first episode of The Last of Us (TV series). As always, check out all the socials (link below), leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:24 News: 00:12:31 Sinister Sneaks: 00:18:47 Last of Us, Episode 1 Discussion: 00:48:00 Outro: 1:00:24 Click here for all our socials! - https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://podcasters.spotify.com/pod/show/matrimony-madness/message

Had no idea this was the dirty 30 episode but boy does it live up to its name. The gang briefly touches on some upcoming gaming event to push forward the festivities as well as the overall woes of being any type of sports fan. Concurrent with last week's episode, we've got another double feature heavy hitter on our hands with the review of Terrifier 2 and Halloween Ends. Movies on polar ends of the spectrum both with polarizing impressions and opinions. CMax apologize in advance… As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:24 News: 00:09:47 Terrifier 2: Non-Spoiler Review: 00:18:40 Terrifier 2: Spoiler Discussion: 00:42:21 Halloween Ends Non-Spoiler Review: 00:55:58 Halloween Ends Spoiler Discussion: 01:15:25 Outro: 01:28:00 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Last week it was baddies and this week it's CMax using the scientific method to process various holiday content. The gang also discusses Regal's next marketing strategy and Scooby Doo for adults. There's also two reviews this episode: Marvel's Werewolf by Night and the newest adaption in the Hellraiser lore, Hellraiser (2022). For the sake of time, both are spoiler reviews so mind your ears! As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:24 News: 00:13:24 Werewolf by Night Review (Spoilers): 00:29:33 Hellraiser (2022) Review (Spoilers): 00:46:36 Outro: 01:06:04 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

We're back from the dead just in time for what is unarguably spooky season for everyone on the Earth. If you say it's not, you're part of the problem. After an absence due to traveling and time constraints, the wedded woeful tackle the most important topic on the show so far: spooky boy baddies. Spooky shows the world how to speedrun the news and CMax breaks down a vast majority of the content coming to your eyes and ears in October, including a jam-packed October 7th. Spooky reviews her September book and the team does their boujeest of reviews; Halloween on a Disney cruise. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 News: 00:10:13 Did They Like It?: 00:22:43 Plastic Monsters Non-Spoiler Book Review: 00:44:57 Halloween on the High Seas Disney Cruise Review (Spoilers): 00:51:43 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

The day CMax was dreading is here and we review his least anticipated and preemptively labeled (before seeing it) most controversial film of the year: Barbarian. Before the craziness ensues, the gang touches on some D23 news and Spooky takes a dive into September's book The Only Good Indians. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 News: 00:06:14 The Only Good Indians Review: 00:18:08 Barbarian Review (Spoiler Free): 00:38:53 Barbarian Review (Spoilers Ahead): 00:54:13 Outro: 01:10:00 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Nicolás García Mayor es el fundador de CMAX, un sistema de alojamiento de emergencia que provee vivienda inmediata para refugiados. En esta entrevista hablamos de mejorar la vida de las personas afectadas por una guerra. Nicolás es un diseñador industrial argentino especializado en desarrollo humanitario y preservación del medio ambiente. En el momento de la charla estaba en Polonia, cerca de Ucrania, ayudando con su sistema de alojamiento en el contexto de la guerra. Después del ataque de Rusia a Ucrania, hay mucha necesidad de espacios nuevos en zonas destruidas. Estos sistemas de alojamiento por ejemplo, funcionan como hospitales móviles. En un momento de crisis se necesitan diferentes soluciones para los muchos y complejos problemas que la situación impone. Esta entrevista es parte de las listas: Argentina y diseño, diseño industrial y Diseño y salud y Diseño sostenible.

Happy birthday to the only scream queen that truly matters in what we consider our immediate universe - our queen; Spooky! The celebration wouldn't be complete without our longest episode to date (we apologize in advance). CMax and Spooky dive fully into Universal Orlando's Halloween Horror Nights with commentary on all scare zones, food options and reviews of each haunted house. The gang also takes a long tenured birthday tradition and brings it into audio format as movies are drafted to compromise what makes up "Spooky's 31 Days of Halloween." As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it! Shout-out to the Little Monsters and Teen Wolves. Have a great Labor Day and a killer week! Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness Intro: 00:00:23 News: 00:09:51 Halloween Horror Nights Review & Discussion: 00:19:39 Spooky's 31 Days of Halloween: 01:31:14 Outro: 01:47:06 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Mama Spook left so the spook is back. After a week with Spooky's mom, the gang is back - still at CMax's mom's house - with another jam packed episode. You'll receive a play-by-play of a neighborhood delivery you didn't ask for from CMax in a euphoric stupor from medicine for his crazy foot. After briefly touching on Locke & Key, the announcements just seem to roll off the tongue. We touch base on the heavy-hitters from Gamescom as well as a big October release schedule. Lastly, we touch base on all the Halloween Horror Nights official announcements with comparisons and contrasts as well as initial thoughts. Hop on next week's episode for our full review of Halloween Horror Nights at Universal Studios Orlando (hurricane pending). As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it! Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 Locke & Key Brief Review: 00:14:06 Gamescom: 00:16:34 News: 00:34:40 Halloween Horror Nights Release Round-Up: 00:42:37 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

This is the LeBron or Jordan episode depending on what team you're on but you can honestly love both. Now that that's out of the way, CMax loses his mind and Spooky is shook after hearing who is playing Hatbox Ghost in Disney's next foray into the Haunted Mansion saga (or franchise?). Matrimony of Madness is excited to present our first ever book club review with August's book being unveiled this week on TikTok. Lastly, did Prey prey on CMax's love for the predator or are we salivating? As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 News: 00:11:33 July's Book Club Review: 00:27:13 Prey (Non-Spoiler Review): 00:42:23 Prey (Spoiler Review): 00:56:24 Outro: 01:03:00 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

You know what's epic? The total destruction of the NWO's Georgia Guidestones and the total implosion of the treacherous Biden presidency. There may be no greater symbol of the tide shifting against the global Luciferian cabal than the demolition of the Guidestones. You know what else is epic? One of my top crypto picks for the next five years - one that I just invested $3,500 of my own money into, and one that I'll share with you for FREE, unlike others in the space. WATCH this episode here: https://www.bitchute.com/video/JxdEVty0gkxM/ Epicentral: http://epicentral.io - Epic Tech: http://epic.tech Facebook: https://www.facebook.com/groups/EpicCashCommunity Linktree: http://linktr.ee/epiccash - Epic Cash Telegram: t.me/EpicCash YouTube: https://www.youtube.com/channel/UCQBFfksJlM97rgrplLRwNUg

Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). On the last full day of the program, several vitally important drug development studies were presented during the late-breaker and dedicated sessions. The conversations in this episode will review some of the most important findings. This particular conversation focuses largely on Stephen Harrison's presentation of results of a Phase 1 trial for pemvidutide, a dual GLP-1/glucagon agonist, at this meeting.The conversation starts with a brief discussion about the appropriate context for using and interpreting FIB-4 results. The closing comment for this discussion comes from Michelle Long, who suggests that use of FIB-4 is context-sensitive: "You have to know what's your question and how are you thinking of using this test" because its usefulness changes depending on the disease prevalence in the population being studied.From here, Stephen starts to discuss a Phase 1 trial for pemvidutide that he presented at #ILC2022. Of the 34 patients in this trial, 8 had fat in their livers; all were overweight or obese. Stephen describes the GLP_1/glucagon combination as being like "not eating and exercising at the same time" because GLP-1s work on satiety control and gastric emptying (not eating) while glucagon increases overall metabolism and specifically revs up lipid metabolism (exercise) "because you're cutting the intake of calories [while] increasing the burn rate through the liver. He goes on to note the reason that by lowering Cmax and increasing Tmax, it demonstrates the pharmacokinetic profile of a q1w drug. Of the 8 patients with measurable liver fat, all dropped below the level of detection at the 1.8 and 2.4 doses (representing a 90% reduction). Stephen closes his discussion of the trial by mentioning dramatic weight loss levels and a 14-15% drop in liver volume over 12 weeks.All the panelists express positive reactions to these results. In response to a question from Roger, Mazen says they are as good as endo-bariatric surgery or better. As the conversation ends, Mazen goes on to ask whether this is an acute or maintenance medication and states he suspects it will be lifetime maintenance.

Spooky and CMax are back after Spooky realized being a 'Dead Head' isn't exactly what she thought it meant. Just kidding. The gang tackles the new trailers and brief news surrounding what's left to be fulfilled this year while the summer drought occurs. Spooky and CMax also banter about the content of various items and review Spooky's boyfriend's new movie, The Black Phone. Word of the episode is also 'freedom.' As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 News: 00:12:45 Sinister Sneaks: 00:15:48 First Kill Initial Thoughts: 00:38:35 Black Phone (Non-Spoiler Review): 00:44:41 Black Phone (Spoiler Review): 00:50:12 Outro: 01:07:38 Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://anchor.fm/matrimony-madness/message

40 State Attorneys General entered into a settlement with Ford Motor Company related to its substantiation of payload capacity claims on certain Super Duty pickup trucks and the fuel economy of certain C-Max hybrids.  Ford is paying $19 million to the participating States, plus $200,000 in costs.  The settlement itself is pretty straightforward – there are only two substantive requirements related to Ford's future conduct.  Going forward, Ford cannot make false or misleading advertising claims regarding the estimated fuel economy or payload capacity of new motor vehicles. https://www.adlawaccess.com/2022/05/articles/state-attorneys-general-hold-ford-accountable-for-advertising-claims/ Paul L. Singer
 psinger@kelleydrye.com
 (202) 342-8672
 Bio - www.kelleydrye.com/Our-People/Paul-L-Singer Beth Chun
 bchun@kelleydrye.com
 (202) 342-8671
 Bio - www.kelleydrye.com/Our-People/Beth-Bolen-Chun Join us for State Attorneys General 101, a webinar covering the basics of State AG consumer protection powers, what to expect if you find yourself a target of attorneys general investigation, how to look to state attorneys general to stop improper actions of competitors, and more. Register here: https://kelleydrye.zoom.us/webinar/register/WN_7WoCzfkuQMuYZH4u-1Lw1g Find all of our consumer protection, advertising, and privacy law updates here https://linktr.ee/KelleyDryeAdLaw Hosted by Simone Roach Produced by Jeff Scurry

After a grueling day in the sun (two for CMax), the gang is here for the tears and jeers. Universal Studios and Monsters were at the forefront of our minds as we speculate what's to come and find solace in putting an OG to rest. Franchises are discussed for some reason? Also, why is August 5th the drop for an insane amount of horror content in the year of 2022? Lastly, a hometown horror convention in its first year is reminisced on and reviewed. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness Intro: 00:00:23 News: 00:05:50 Sinister Sneaks: 00:25:09 Spookala Review: 00:40:13 Outro: 10:04:40 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Welcome to our first ever Little Monsters special edition of Matrimony of Madness. Today is devoted to the spooky kids we love so much and we hope you enjoy this episode as much as we enjoyed making it. The Little Monsters discuss horror characters, body functions and participate in our Little Monsters Night Visions game show. Spooky & CMax also dive into the Alan Wake TV show announcement. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 Little Monsters: 00:03:13 Night Visions: 00:13:23 News: 00:38:17 Alan Wake TV Show Announcement: 00:43:09 Outro: 00:48:19 Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Another short one but after a Disney cruise and COVID, we're just happy we're not six feet under. Spooky & CMax take a swirl around the horror world the past two weeks ending in a ranking and evaluation of The Evil Dead franchise. On the mend and onward through the rest of May. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://anchor.fm/matrimony-madness/message

We didn't plan anything for our unlucky 13th episode and that's about as Matrimony of Madness as you can get. This week the gang is ready to get away... in a good way as they set sail for a Disney cruise next week. This brief, but fun episode touches on CMax's new Hot Wheels obsession, and how our hearts are broken from Nosferatu becoming "NO"sferatu. There's also a brief vacation vignette where we indulge in some spooky travel hot spots! As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro: 00:00:23 News: 00:10:39 Vacation Vignette: 00:21:01 Outro: 00:36:23 Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://anchor.fm/matrimony-madness/message

CMax had a killer week and is feeling much better, as is Spooky after her coffee and nappy. Your favorite perilous duo is back with another look into potential houses for these year's Halloween Horror Nights. As promised, there are also several Sinister Sneaks including an insane spot from a legend and a look into our next trip to Hawkins. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters and Teen Wolves. We love you all. Have a killer week! Intro - 00:00:23 News - 00:10:54 Halloween Horror Nights Speculation 2.0 - 00:21:23 Sinister Sneaks - 0046:16 Stranger Things Season 3 Trailer - 00:57:33 Outro - 01:03:13 Click our linkt.ree below to stalk us on social media! https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://anchor.fm/matrimony-madness/message

There's something in the air and it didn't come from CMax's DERRY-air! However, mews of a new Pennywise installment has your favorite spooky couple speculating and insinuating. CMax is doing better after demonstrating anxiety in the form of a podcast introduction. The gang covers the news missed the past few weeks and goes on a few conversational bingers along the way. There's also a winner of this year's 2022 Matrimony of March Madness. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters We love you. Have a killer week!  Intro: 00:00:23 News: 00:12:47 Returning to Derry: 00:26:16 Matrimony of March Madness Conclusion: 00:33:09 Outro: 00:55:13 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Your favorite horror couple dives into some really God tier announcements and disappointments as we analyze why Netflix is literally the best and the worst at the same time? We take a further look into a new trailer for a highly anticipated A24 film coming this year, along with a meme of the show and one of our favorite franchises coming back in the best way possible. Lastly, we finalize our Final Four of our Matrimony of March Madness tournament and CMax publicly apologizes to the state of California with brief coverage of the Halloween Horror Nights 31 Hollywood Studios map. As always, check out all the socials, leave a review on your favorite podcatcher and we appreciate you taking a stab at it. Shout-out to the Little Monsters. Have a killer week! Intro: 00:00:23 News: 00:07:57 Sinister Sneaks: 00:21:45 March Madness - Elite Eight: 00:35:38 Halloween Horror Nights Speculation Map - Hollywood, CA: 00:53:43 Outro: 00:57:49 Stalk us on all our socials! Click the link below! https://linktr.ee/Matrimonyofmadness --- Send in a voice message: https://anchor.fm/matrimony-madness/message

Ashes to ashes and pardon our dust. A little R&R last week has put Spooky on a vengeance this week as she lets the deflating of CMax's being flow wildly through her… in good fun of course. The gang discusses all the big show, movie and video game news the past couple of weeks including David Arquette as a park ranger in a new upcoming project. The unofficial Halloween Horror Nights map is being speculated on and may be our first unofficial “Final Girl” award. The episode finishes with the Sweet 16 of our Matrimony of March Madness tournament. Out of nowhere, CMax also answers the ULTIMATE QUESTION. We love you all. Be sure to follow on all social media pages and give a review if the skin fits. Shout-out to the Little Monsters! Have a killer week! Intro: 00:00:23 News: 00:09:04 Halloween Horror Nights 31 Speculation: 00:23:17 Matrimony of March Madness, Round of 16: 00:39:53 Outro: 00:58:28 --- Send in a voice message: https://anchor.fm/matrimony-madness/message

In this special live episode Nick is joined by Ashley Zahorian, president and CEO of CMAX.tv! Ashley discusses what CMAX TV does, how they give Christian artists a platform for producing good media, and how they stay true to their Catholic values.This episode is sponsored by Select International Tours and Cruises. Learn more at http://selectinternationaltours.com/awaken https://TheAwakenCatholicShow.com Not your grandmother's Catholic talk show. Join Nick De La Torre in hilarious, thought-provoking, and tear jerking conversations about faith, life, and God. Join the COMMUNION OF sAINTS patron community for exclusive access and benefits at https://TheAwakenCatholicShow.com Get the AWAKEN Catholic app at https://theawakenapp.io #travelwithselect #sekectinternationaltours